(PTGX) Protagonist Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 6.315m USD | Total Return: 123.2% in 12m

Stock Oral Peptides, Injectable Peptides, Small Molecules
Total Rating 48
Safety 36
Buy Signal 0.55
Biotechnology +0.2
Biotechnology +1.0
Market Cap: 6,315m
Avg Trading Vol: 82.6M USD
ATR: 4.66%
Peers RS (IBD): 72.3
Risk 5d forecast
Volatility50.6%
Rel. Tail Risk-11.3%
Reward TTM
Sharpe Ratio1.71
Alpha112.76
Character TTM
Beta-0.098
Beta Downside-1.725
Drawdowns 3y
Max DD52.15%
CAGR/Max DD1.35
EPS (Earnings per Share) EPS (Earnings per Share) of PTGX over the last years for every Quarter: "2021-03": -0.54, "2021-06": -0.69, "2021-09": -0.7, "2021-12": -0.77, "2022-03": -0.43, "2022-06": -0.84, "2022-09": -0.64, "2022-12": -0.69, "2023-03": -0.67, "2023-06": -0.68, "2023-09": -0.58, "2023-12": 0.44, "2024-03": 3.26, "2024-06": -0.5, "2024-09": -0.54, "2024-12": 1.98, "2025-03": -0.19, "2025-06": -0.55, "2025-09": -0.62, "2025-12": -0.69, "2026-03": 0,
EPS CAGR: 103.40%
EPS Trend: 18.1%
Last SUE: 0.54
Qual. Beats: 0
Revenue Revenue of PTGX over the last years for every Quarter: 2021-03: 6.189, 2021-06: 2.265, 2021-09: 10.286, 2021-12: 8.617, 2022-03: 25.722, 2022-06: 0.859, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 60, 2024-03: 254.953, 2024-06: 4.167, 2024-09: 4.675, 2024-12: 170.638, 2025-03: 28.321, 2025-06: 5.546, 2025-09: 4.712, 2025-12: 7.437, 2026-03: null,
Rev. CAGR: -28.17%
Rev. Trend: 40.4%
Last SUE: -0.08
Qual. Beats: 0
Risks
Technicals: choppy
Description: PTGX Protagonist Therapeutics

Protagonist Therapeutics, Inc. (PTGX) is a US-based biotechnology company focused on discovering and developing peptide-based therapies.

The companys pipeline includes Icotyde for plaque psoriasis and Rusfertide, a Phase 3 candidate for polycythemia vera, a rare blood disorder. Peptide therapeutics represent a growing area in drug development due to their specificity and reduced toxicity profiles.

Additional programs target immune-mediated skin diseases and obesity. PTGXs business model involves advancing investigational drugs through clinical trials, a common practice in the biotechnology sector where successful drug development can lead to significant market opportunities.

Further research on ValueRay can provide detailed financials and competitive landscape analysis.

Headlines to Watch Out For
  • Rusfertide clinical trial results significantly impact stock valuation
  • Icotyde regulatory approval determines market entry
  • Pipeline development success drives future revenue potential
  • Competition from established pharmaceutical companies affects market share
  • Research and development expenses influence profitability
Piotroski VR‑10 (Strict) 2.0
Net Income: -130.1m TTM > 0 and > 6% of Revenue
FCF/TA: 0.09 > 0.02 and ΔFCF/TA -15.94 > 1.0
NWC/Revenue: 1.16k% < 20% (prev 125.3%; Δ 1.03k% < -1%)
CFO/TA 0.09 > 3% & CFO 57.7m > Net Income -130.1m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 12.71 > 1.5 & < 3
Outstanding Shares: last quarter (63.6m) vs 12m ago -4.27% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 6.51% > 50% (prev 58.33%; Δ -51.83% > 0%)
Interest Coverage Ratio: -9.57 > 6 (EBITDA TTM -143.1m / Interest Expense TTM -15.1m)
Altman Z'' -7.39
A: 0.79 (Total Current Assets 577.6m - Total Current Liabilities 45.4m) / Total Assets 669.9m
B: -0.70 (Retained Earnings -470.7m / Total Assets 669.9m)
C: -0.20 (EBIT TTM -144.4m / Avg Total Assets 707.3m)
D: -8.52 (Book Value of Equity -470.0m / Total Liabilities 55.2m)
Altman-Z'' Score: -7.39 = D
Beneish M -4.00
DSRI: 0.25 (Receivables 4.50m/168.5m, Revenue 46.0m/434.4m)
GMI: 1.00 (GM 99.18% / 99.47%)
AQI: 0.64 (AQ_t 0.12 / AQ_t-1 0.19)
SGI: 0.11 (Revenue 46.0m / 434.4m)
TATA: -0.28 (NI -130.1m - CFO 57.7m) / TA 669.9m)
Beneish M-Score: -4.78 (Cap -4..+1) = AAA
What is the price of PTGX shares? As of April 05, 2026, the stock is trading at USD 105.40 with a total of 781,528 shares traded.
Over the past week, the price has changed by +4.86%, over one month by +13.67%, over three months by +23.28% and over the past year by +123.18%.
Is PTGX a buy, sell or hold? Protagonist Therapeutics has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy PTGX.
  • StrongBuy: 5
  • Buy: 4
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the PTGX price?
Wallstreet Target Price 112.4 6.7%
Analysts Target Price 112.4 6.7%
PTGX Fundamental Data Overview as of 05 April 2026
P/E Forward = 23.6967
P/S = 137.2381
P/B = 10.2703
Revenue TTM = 46.0m USD
EBIT TTM = -144.4m USD
EBITDA TTM = -143.1m USD
Long Term Debt = 10.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.28m USD (from shortTermDebt, last quarter)
Debt = 10.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -118.1m USD (from netDebt column, last quarter)
Enterprise Value = 5.76b USD (6.32b + Debt 10.3m - CCE 567.4m)
Interest Coverage Ratio = -9.57 (Ebit TTM -144.4m / Interest Expense TTM -15.1m)
EV/FCF = 99.84x (Enterprise Value 5.76b / FCF TTM 57.7m)
FCF Yield = 1.00% (FCF TTM 57.7m / Enterprise Value 5.76b)
 FCF Margin = 125.3% (FCF TTM 57.7m / Revenue TTM 46.0m)
 Net Margin = -282.8% (Net Income TTM -130.1m / Revenue TTM 46.0m)
 Gross Margin = unknown ((Revenue TTM 46.0m - Cost of Revenue TTM 376k) / Revenue TTM)
 Tobins Q-Ratio = 8.60 (Enterprise Value 5.76b / Total Assets 669.9m)
Interest Expense / Debt = 22.24% (Interest Expense 2.30m / Debt 10.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -114.1m (EBIT -144.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.71 (Total Current Assets 577.6m / Total Current Liabilities 45.4m)
Debt / Equity = 0.02 (Debt 10.3m / totalStockholderEquity, last quarter 614.7m)
 Debt / EBITDA = 0.82 (negative EBITDA) (Net Debt -118.1m / EBITDA -143.1m)
 Debt / FCF = -2.05 (Net Debt -118.1m / FCF TTM 57.7m)
Total Stockholder Equity = 654.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -18.40% (Net Income -130.1m / Total Assets 669.9m)
RoE = -19.89% (Net Income TTM -130.1m / Total Stockholder Equity 654.3m)
RoCE = -21.73% (EBIT -144.4m / Capital Employed (Equity 654.3m + L.T.Debt 10.3m))
 RoIC = -17.44% (negative operating profit) (NOPAT -114.1m / Invested Capital 654.3m)
 WACC = 5.66% (E(6.32b)/V(6.33b) * Re(5.64%) + D(10.3m)/V(6.33b) * Rd(22.24%) * (1-Tc(0.21)))
Discount Rate = 5.64% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 33.33 | Cagr: 1.43%
[DCF] Terminal Value 80.82% ; FCFF base≈107.7m ; Y1≈70.7m ; Y5≈32.3m
[DCF] Fair Price = 17.94 (EV 1.03b - Net Debt -118.1m = Equity 1.14b / Shares 63.8m; r=6.0% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 18.07 | EPS CAGR: 103.4% | SUE: 0.54 | # QB: 0
Revenue Correlation: 40.35 | Revenue CAGR: -28.17% | SUE: -0.08 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.41 | Chg7d=+0.209 | Chg30d=+0.101 | Revisions Net=-2 | Analysts=7
EPS current Year (2026-12-31): EPS=2.77 | Chg7d=+0.020 | Chg30d=+1.205 | Revisions Net=-3 | Growth EPS=+235.3% | Growth Revenue=+860.1%
EPS next Year (2027-12-31): EPS=-0.43 | Chg7d=+0.151 | Chg30d=+0.512 | Revisions Net=-4 | Growth EPS=-115.7% | Growth Revenue=-64.8%
[Analyst] Revisions Ratio: -0.50 (1 Up / 3 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle